- 1 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
- 2 fishery vessel outbreak with high attack rate
- 4 Amin Addetia¹, Katharine HD Crawford^{2,3,4}, Adam Dingens², Haiying Zhu¹, Pavitra
- Roychoudhury^{1,5}, Meei-Li Huang^{1,5}, Keith R. Jerome^{1,5}, Jesse D. Bloom^{2,3,6}, Alexander 5
- 6 L. Greninger^{1,5,#}

7

- 8 ¹ Department of Laboratory Medicine and Pathology, University of Washington School
- 9 of Medicine, Seattle, WA
- ² Division of Basic Sciences and Computational Biology Program, Fred Hutchinson 10
- 11 Cancer Research Center, Seattle, WA
- 12 ³ Department of Genome Sciences, University of Washington, Seattle, WA
- 13 ⁴ Medical Scientist Training Program, University of Washington, Seattle, WA
- 14 ⁵ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center,
- 15 Seattle, WA

18

20

21

22

- ⁶ Howard Hughes Medical Institute, Seattle, WA 16
- # Corresponding author, agrening@uw.edu 17
- 19 Running title: SARS-CoV-2 protection in humans

Abstract

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the identification of immunological correlates of protection in humans. However, to date, studies on protective immunity have only been performed in animal models and correlates of protection have not been established in humans. Here, we describe an outbreak of SARS-CoV-2 on a fishing vessel associated with a high attack rate. Predeparture serological and viral RT-PCR testing along with repeat testing after return to shore was available for 120 of the 122 persons on board over a median follow-up of 32.5 days (range 18.8 to 50.5 days). A total of 104 individuals had an RT-PCR positive viral test with Ct <35 or seroconverted during the follow-up period, yielding an attack rate on board of 85.2% (104/122 individuals). Metagenomic sequencing of 39 viral genomes suggested the outbreak originated largely from a single viral clade. Only three crewmembers tested seropositive prior to the boat's departure in initial serological screening and also had neutralizing and spike-reactive antibodies in follow-up assays. None of these crewmembers with neutralizing antibody titers showed evidence of bona fide viral infection or experienced any symptoms during the viral outbreak. Therefore, the presence of neutralizing antibodies from prior infection was significantly associated with protection against re-infection (Fisher's exact test, p=0.002).

Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused tens of millions of infections and hundreds of thousands of deaths worldwide since its emergence in December 2019. Multiple vaccine candidates are currently in Phase III trials (1–3). The success of these vaccines could be helped by further insights into the protective nature of neutralizing antibodies in humans. Neutralizing antibodies have been isolated from individuals previously infected with SARS-CoV-2 (4, 5). These antibodies often target the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein and prevent the binding interaction between the spike protein and the host's angiotensin-converting enzyme 2 (ACE2) (4, 5), although neutralizing antibodies that do not inhibit spike's binding to ACE2 have also been identified (6, 7). In animal models, neutralizing antibodies are protective against SARS-CoV-2 (8, 9). Vaccines currently in development against SARS-CoV-2 have been shown to elicit levels of neutralizing antibodies comparable to those observed in naturally infected persons (1–3). However, the protective nature of both vaccine- and infection-elicited neutralizing antibodies in humans remains unproven, with animal models being used to make inferences about protection (10, 11). Human challenge trials, which could provide rapid information about the protection conferred by neutralizing antibodies (12, 13), are controversial due to the severity and unknown long-term impacts of SARS-CoV-2 infection and concerns over ethical administration of such trials (14, 15). Given the high number of people exposed to SARS-CoV-2 every day, retrospective analyses of outbreak events may provide insights into the protective

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

nature of neutralizing antibodies. In particular, outbreaks on confined shipping vessels are particularly useful candidates for assessing protection from SARS-CoV-2 infection (16–18). The high population density and large degree of contact between people on ships contributes to a high attack rate. In some cases nearly all passengers will have been exposed (16). Here, we performed a retrospective analysis of a SARS-CoV-2 outbreak on a fishing vessel that departed from Seattle, Washington in May 2020. Predeparture viral and serological testing was performed on the near entirety of the ship's crew, allowing for testing of how pre-existing immunity correlated with subsequent infection during the outbreak. **Methods** Clinical diagnostic testing Nasopharyngeal swabs were collected from patients in 3 mL of viral transport media. RT-PCR testing was performed on either the Hologic Panther Fusion, Roche cobas 6800, or the University of Washington CDC-based, emergency use authorized laboratory developed test (19). Clinical testing of serum samples was performed using the Abbott Architect SARS-CoV-2 IgG assay (20). Index values associated with the Abbott test are chemiluminescent signal values relative to a calibrator control, and are broadly similar to O.D. values for an ELISA. An index value ≥ 1.40 is qualitatively reported as positive. The case definition for an individual infected on the boat included

anyone with a positive RT-PCR with Ct < 35 or seroconversion by the Abbott test during

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

the follow-up period. This study was approved by the University of Washington Institutional Review Board. SARS-CoV-2 whole genome sequencing RNA was extracted from positive SARS-CoV-2 samples using the Roche MagNA Pure 96 (21). Metagenomic sequencing libraries were constructed as previously described (22). Briefly, RNA was DNAse-treated using the Turbo DNA-Free Kit (Thermo Fisher). First strand cDNA was synthesized using Superscript IV (Thermo Fisher) and 2.5µM random hexamers (IDT) and second strand synthesis was performed with Sequenase Version 2.0 DNA Polymerase (Thermo Fisher). The resulting double-stranded cDNA was purified using 1.6X volumes of AMPure XP beads (Beckman Coulter). Libraries were constructed using the Nextera DNA Flex Pre-Enrichment kit (Illumina) and cleaned using 0.7X volumes of AMPure XP beads. The resulting libraries were sequenced on a 1x75 bp Illumina NextSeg run. A median of 509,551 seguencing reads were obtained for each sample. Sequencing reads are available at NCBI BioProject PRJNA610428 and sequence accessions are available in Supplemental Table 1. Consensus genomes were called using a custom SARS-CoV-2 genome calling pipeline (https://github.com/proychou/hCoV19). Briefly, sequencing reads were adapterand quality-trimmed with BBDuk and mapped to the SARS-CoV-2 reference genome (NC 045512.2) using Bowtie 2 (23). Reads aligning to the SARS-CoV-2 reference genome were filtered using BBDuk and assembled with SPAdes (24). The de novo assembled contigs and mapped read assemblies were merged to produce a consensus genome. For samples that did not produce a genome through the automated pipeline,

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

ELISA, and pseudovirus neutralization.

the mapped read assemblies were visualized in Geneious and a consensus genome was called manually. A phylogenetic analysis was completed using the 39 consensus genomes obtained through metagenomic sequencing and 109 other SARS-CoV-2 isolates downloaded from https://www.gisaid.org/ (accessed July 17, 2020) reflective of the global genomic diversity of SARS-CoV-2. To select 109 SARS-CoV-2 isolates, all global SARS-CoV-2 sequences were downloaded from GISAID. Those composed of >5% Ns, those with disrupted reading frames, and those with partial genomes were discarded. The strains were then stratified by Pangolin lineage (A or B) (https://github.com/covlineages/pangolin) and 49 from lineage A and 59 from lineage B were randomly selected along with the Wuhan-Hu-1 reference genome (NC 045512.2) (25). Sequences were aligned with MAFFT v7.453 (26) and a phylogenetic tree was constructed using FastTree (version 2.1.1) (27) with the 5' and 3'UTRs masked. The resulting phylogenetic tree was visualized in R (version 3.6.1) using the agtree package (28). Strains most closely related to the major outbreak clade were identified by searching against a custom BLASTN database containing all SARS-CoV-2 seguences in GISAID (accessed August 3, 2020). Neutralization Assays and Anti-Spike Antibody Testing The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the Abbott assay screening through four different methods: Spike IgG ELISA, RBD ELISA, ACE2 blockade of binding

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

RBD and spike protein for the ELISAs were produced as described previously (29). IgG enzyme-linked immunosorbent assays (ELISAs) to spike and RBD were adapted from published protocol (30, 31), with details described previously (32). Spike or RBD was diluted to 2 μg/mL in PBS and 50 μL/well was used to coat 96 well Immunion 2HB plates (Thermo Fisher; 3455) at 4°C overnight. Plates were washed three times the next day with PBS containing 0.1% Tween 20 (PBS-T) using a Tecan HydroFlex plate washer. Plates were blocked for 1 hour with 200 µL/well of 3% non-fat dry milk in PBS-T at room temperature. Sera were diluted 4-fold in PBS-T containing 1% non-fat dry milk, starting at a 1:25 dilution. Pooled sera collected from 2017-2018 from 75 individuals (Gemini Biosciences, 100-110, lot H86W03J) and CR3022 antibody (starting at 1/ug/mL, also diluted 4-fold) were included as negative and positive controls, respectively. After block was thrown off plates, 100µL diluted sera was added to plates and incubated at room temperature for 2 hours. Plates were again washed three times, and then 50µL of a 1:300 dilution of goat anti-human IgG-Fc horseradish peroxidase (HRP)-conjugated antibody (Bethyl Labs, A80-104P) in PBS-T containing 1% milk was added to each well and incubated for 1 hour at room temperature. Plates were again washed three times with PBS-T. 100µL of TMB/E HRP substrate (Millipore Sigma; ES001) was then added to each well, and after a 5-minute incubation, 100 µL 1N HCl was added to stop the reaction. OD450 values were read immediately on a Tecan infinite M1000Pro plate reader. Area under the titration curve (AUC) was calculated with the dilutions on a log-scale. The ACE2 blockage of binding assay was performed using the SARS-CoV-2 Surrogate Virus Neutralization Test Kit (GenScript). The assay was performed following

the manufacturer's recommendations with 10µL serum diluted into 90µL dilution buffer and read using the DS2 microplate reader (Dynex technologies).

Neutralization assays with spike-pseudotyped lentiviral particles were performed as described previously (33), with a few modifications. Briefly, cells were seeded in black-walled, clear bottom, poly-L-lysine coated 96-well plates (Greiner, 655936). About 14 hours later, serum samples were diluted in D10 media (DMEM with 10% heatinactivated FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin) starting with a 1:20 dilution followed by 6 serial 3-fold dilutions. An equal volume of full-length spike-pseudotyped lentiviral particles as diluted serum was added to the serum dilutions and incubated at 37C for 1 hour. 100µL of the virus plus serum dilutions were then added to the cells ~16 hours after the cells were seeded.

About 52 hours post-infection, luciferase activity was measured as described previously (33) except luciferase activity was read out directly in the assay plates without transferring to black, opaque bottom plates. Two "no serum" wells were included in each row of the neutralization plate and fraction infectivity was calculated by dividing the luciferase readings from the wells with serum by the average of the "no serum" wells in the same row. After calculating the fraction infectivity, we used the neutcurve Python package (https://jbloomlab.github.io/neutcurve/) to calculate the serum dilution that inhibited infection by 50% (IC50) by fitting a Hill curve with the bottom fixed at 0 and the top fixed at 1. All serum samples were measured in duplicate. To calibrate our neutralization assays, we also ran them on the NIBSC reference serum sample (product number 20/130) and measured an IC50 of 1:2395.

Results

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Predeparture PCR and serology testing

There were a total of 122 people (113 men and 9 women) on the manifest of the ship.

Prior to the ship's departure, crewmembers were screened for active SARS-CoV-2

infection by RT-PCR, or for serological evidence of prior or ongoing infection using the

Abbott Architect assay which detects antibodies against the viral nucleoprotein (N).

Predeparture RT-PCR and serology test data were available for 120 crewmembers.

This predeparture screening occurred on Day 0 and Day 1 prior to the ship's departure

on Day 2. In this predeparture screening, none of the crewmembers tested positive for

virus by RT-PCR, and six individuals tested seropositive in the Abbott Architect assay

(index value ≥1.40) (Figure 1A).

Table 1. Laboratory values for crew members who were pre-departure seropositive by Abbott SARS-CoV-2

_			Day 0-1									
		Abbott IgG	Neutralization	ACE2	RBD IgG	spike IgG	Day 18-21	Day 25-26	Day 28	Day 31-36	Day 31-35	Day 31-35
Sample	RT-PCR	index	IC50	BoB	AUC	AUC	PCR (Ct)	PCR	PCR	PCR	Abbott IgG index	ACE2 BoB
2020-00350	negative	6.93	1:174	89%	15.62	17.15	negative	negative	n.d.	negative	6.40	95%
2020-00369	negative	4.07	1:161	84%	10.98	14.27	negative	n.d.	n.d.	negative	2.93	68%
2020-00381	negative	4.72	1:3082	93%	10.56	14.48	negative	37.4	negative	38.3	3.48	90%
2020-00394	negative	1.62	>1:20	-4%	1.46	4.13	22.91	n.d.	n.d.	27.9	4.29	30%
2020-00418	negative	3.81	>1:20	3%	0.47	2.27	22.84	n.d.	n.d.	30.4	6.31	93%
2020-00348	negative	1.48	>1:20	0%	0.37	2.72	17.57	n.d.	n.d.	negative	5.98	35%

n.d., not done; BoB, blockade of binding

After becoming aware of the subsequent SARS-CoV-2 outbreak on the ship (see next section), we tested residual predeparture serum samples from the six individuals who were seropositive in the Abbott Architect assay to characterize the neutralizing and spike-binding activity of their sera. The sera of three of these six individuals had potent neutralizing activity against SARS-CoV-2 spike pseudotyped lentiviral particles (Table 1, Figure 1B). The neutralizing titers (1:174, 1:161, 1:3082) are in the typical range of titers

observed in humans who have been infected with SARS-CoV-2 within the previous few months (29, 34, 35). The sera of the three individuals with neutralizing titers also had high activity in an assay that measure the ability of antibodies to block RBD binding to ACE2, as well as in IgG ELISAs against spike and RBD (Table 1, Figure 1C).




Figure 1 – Pre-departure serological assays. A) Abbott Architect index values for all 120 individuals assayed. The grey line indicates the cutoff for a positive Abbott reading (≥ 1.40). Individuals with negative Abbott index values are further classified by whether they subsequently became infected on the ship. Individuals with positive Abbott index values are further characterized by whether their pre-boarding serum was neutralizing. B) Neutralization curves for all 6 pre-boarding samples that were positive in the Abbott Architect assay. C) Titers of RBD- or Spike-binding IgG antibodies in all 6 Abbott positive pre-boarding samples as measured by ELISA. The negative control sample is pooled sera collected in 2017-2018 from 75 individuals (Gemini Biosciences, 100-110, lot H86W03J).

Notably, the sera of the other three individuals who were seropositive in the Abbott Architect assay but did not have neutralizing activity had lower quantitative readings in the Abbott assay (including two that were close to the cutoff of 1.40; Figure 1A) and readings comparable to those from negative controls in the RBD and spike ELISA assays (Figure 1C). Therefore, we speculate that the three individuals without neutralizing activity were false positives in the initial serological screening. However, they could have been in the early stages of active infection, since the Abbott Architect detects antibodies against N while all the other assays we used detect antibodies against spike, and anti-N antibodies appear earlier after infection than anti-spike

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

antibodies (36, 37). Alternatively, they could have experienced a mild or asymptomatic infection, which can be associated with transient or low-level seroconversion (38, 39). Overall, assuming that only individuals who were positive in the initial Abbott Architect assay have neutralizing anti-spike antibodies, then just three of the 120 individuals with pre-departure screening data had neutralizing antibodies prior to boarding the ship. We consider this assumption to be well supported by several lines of evidence: large-scale studies have demonstrated that the Abbott Architect has close to 100% sensitivity by two weeks post-symptom onset (20); numerous studies (36, 37) have shown that SARS-CoV-2 infected patients almost invariably mount strong and early antibody responses to the N antigen detected by the Abbott Architect; and a study (32) using the exact assays described here found that only individuals with anti-N antibodies have neutralizing titers to SARS-CoV-2. Testing after ship returned due to outbreak On Day 18, the ship returned to shore after a crewmember became sick, tested positive for SARS-CoV-2, and required hospitalization. Testing data after return was available for all 122 crewmembers for RT-PCR and 114 crewmembers for serology using the Abbott assay. RT-PCR and serological testing was performed until day 50, leading to a median follow-up of 32.5 days (range 18.8 to 50.5 days). Of the 118 individuals with RT-PCR results from the week of return, 98 tested positive with a Ct < 35. Three additional crewmembers tested positive by RT-PCR with a Ct < 35 within the next 10 days. The median of the strongest/minimum Ct for each of

these 101 crewmembers who tested positive with Ct < 35 was 22.8 (IQR 19.3 – 26.9). Serological responses among these individuals as measured by Abbott SARS-CoV-2 IgG index value increased for the majority of these individuals (Figure 2A).




Figure 2 – Return to shore testing. A) Abbott Architect SARS-CoV-2 index values over time (pre- and post-departure) are depicted for each individual with at least 2 serum draws. The dashed line denotes the seropositivity cutoff of the assay (1.40). Individuals who had a positive RT-PCR with Ct < 35 or who seroconverted during the follow-up period are shown in light blue. Individuals who were not infected by the above case definition criteria are shown in green. Individuals who screened positive by the Abbott Architect SARS-CoV-2 IgG assay but lacked neutralizing antibodies and were infected are shown in brown. Individuals who had pre-existing neutralizing antibodies and were not infected are shown in blue. B) SARS-CoV-2 whole genome sequencing of cases from the fishery vessel confirms outbreak. SARS-CoV-2 genomes from 39 cases with Ct < 26 were recovered and a phylogenetic tree was made using FastTree along with 109 other isolates reflective of global diversity. 38 cases are highlighted in red with a median pairwise difference of 1 single nucleotide variant, while one outlier case from the boat is shown with a red dot. Clade A strains associated with early trans-Pacific transmission are shown in purple.

Among the 21 crewmembers who never had a positive RT-PCR test with Ct < 35, three individuals seroconverted based on Abbott Architect index value during the follow-up period. Two of these three crewmembers had positive RT-PCR values with Ct values > 35, while RT-PCR data was not available for the third until Day 49. These three individuals were considered infected on the vessel. In addition, three of the 21 crewmembers without a positive RT-PCR result with Ct < 35 were not tested by

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

serology after returning to shore, though two of the three crewmembers tested negative 3 and 4 times, respectively, by RT-PCR over three weeks after returning. Confirmation of outbreak with whole genome sequencing Metagenomic recovery of 39 SARS-CoV-2 whole genomes from the outbreak indicated a major single outbreak clade (FastTree support value: 1.00) covering 38 isolates that differed by a median of one nucleotide across the genome (range 0-5) (Figure 2B). Sixteen of these isolates shared completely identical sequence. The closest SARS-CoV-2 whole genome sequences in GISAID (August 3, 2020) to the major outbreak clade were strains from Virginia (USA/VA-DCLS-0561/2020), New York City (USA/NY-NYUMC650, NYUMC624, NYNYUMC474, NYUMC426/2020), Minnesota (USA/MN-MDH-1288/2020), or Michigan (USA/MI-MDHHS-SC20223/2020) at 2 SNVs apart. The three crewmembers with neutralizing antibodies were protected from infection We can assess the effects of pre-existing neutralizing antibodies on infection during the outbreak using the pre-departure serological screening (available for 120 of 122 individuals) and the subsequent testing of all 122 individuals for infection. None of the three individuals who had neutralizing antibodies prior to departure were infected during the subsequent outbreak using our case definition of a positive RT-PCR test with Ct < 35 or seroconversion, and none reported any symptoms upon return to shore. In contrast, among the other 117 of 120 individuals with pre-departure serological data who were seronegative or lacked spike-reactive antibodies prior to departure, 103 of 117 were infected using the same case definition (of the 2 individuals without predeparture serological screening, one tested positive and one tested negative by RT-PCR on return). Therefore, the overall rate of infection was 0 of 3 among individuals with neutralizing antibodies, and 103 of 117 among individuals without such antibodies. This difference is statistically significant (Table 2, Fisher's exact test P = 0.002), indicating that pre-existing neutralizing antibodies are significantly associated with protection against SARS-CoV-2 infection.

Table 2. Summary table of infection status of crew members for which pre-departure serology testing was performed.

Pre-departure

		Neutralizing Ab (+)	Neutralizing Ab (-)
On boat	Infected	0	103
On boat	Not Infected	3	14

p=0.0024

The three crewmembers who were seropositive for anti-N antibodies by Abbott but did not have neutralizing antibodies were all infected during follow-up, with minimum Cts of 17.6, 22.8, and 22.9 and increases in Abbott index values (Table 1). Sex did not differ between uninfected and infected, with females composing 5.6% (1 of 18) and 7.7% (8 of 104) of these two groups, respectively (Fisher's exact test, p=1).

We also looked in detail at the viral testing results of the three crewmembers who were positive for neutralizing antibodies to assess the strength of the evidence that they were not re-infected during this ship outbreak. Two tested fully negative by RT-PCR on 3+ occasions, with negative tests on Days 18, 25, 35, and 36 and Days 18, 35, and 36. The third individual tested negative on the Roche cobas on Day 21 and Day 28, and positive only by the E-gene primers/probe set (Ct 37.4) and negative by the orf1ab

primer set on the Roche cobas on Day 25. This individual also tested positive (Ct 38.3) on Day 31 on the Hologic Panther Fusion. By our case definition (which required a positive RT-PCR test with Ct < 35), these results are not consistent with being infected on the boat. The sporadic high-Ct results could be consistent with intermittent, low-level shedding associated with recent past infection, as low levels of SARS-CoV-2 have been detected in nasal passages for more than 80 days (40). Of note, only two other crewmembers had a minimum Ct > 35 in the post-departure follow-up period and both of these individuals were considered infected due to seroconversion during the follow-up period. In contrast, Abbott index values decreased for all three of the crewmembers with predeparture neutralizing antibodies during the follow-up period.

Discussion

Here, we report an outbreak of SARS-CoV-2 on a fishing vessel with an attack rate greater than 85%. Screening with the Abbott Architect anti-nucleocapsid IgG antibody test followed by confirmation of positives with multiple anti-spike protein antibody tests including neutralization assays demonstrated the protective nature of neutralizing antibodies. In particular, none of the three individuals with pre-existing neutralizing antibodies were infected, whereas the vast majority of other individuals were infected. These findings are consistent with data from animal models, in which the elicitation of high titers of neutralizing antibodies was protective against re-challenge with SARS-CoV-2 (8, 10, 41).

An assumption of our analysis is that the only individuals who had pre-existing neutralizing and anti-spike antibodies were those who tested seropositive in the initial

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

pre-departure Abbot Architect anti-N serological screening, since only individuals positive in that screening were subjected to additional serological assays for anti-spike and neutralizing antibodies. However, this assumption is well supported by the validated high sensitivity of the Abbott Architect assay (20), plus the well-established fact that anti-N antibodies appear earlier that anti-spike antibodies (36, 37). Additionally, our four anti-spike antibody tests showed a high level of consistency among seropositive samples, and prior work using the exact same assays has found neutralizing antibodies only among individuals who were positive in the Abbott Architect assay (32). As shown by others, the RBD ELISA and neutralizing antibody assays were highly consistent (42. 43). The ACE2 blockade of binding functional ELISA assay showed excellent consistency with the more laborious pseudovirus neutralizing antibody assay (44). It is intriguing that one individual who had predeparture neutralizing antibodies and was classified as uninfected by our case definition nonetheless had a sporadic very weak signal in viral testing on two different RT-PCR platforms. It is well-established that SARS-CoV-2 can be detected for multiple weeks in the nasopharyngeal tract, well after the resolution of symptoms and elicitation of an antiviral immune response (45, 46). However, it is unclear at this time whether immunity to SARS-CoV-2 will be sterilizing (10, 47), and it is possible that the sporadic weak signal in viral testing for this individual was the result of re-exposure to virus on the boat. In prior studies, the Abbott SARS-CoV-2 IgG assay has shown excellent performance characteristics with high specificity (99.1-99.9%) for prior infection with SARS-CoV-2 (20, 48, 49). Curiously, the positive predictive value for the Abbott SARS-CoV-2 IgG assay for neutralizing antibodies or protection in our population was only

50% (3/6 crewmembers). It is difficult to conclusively determine whether these represented false positives or just anti-N/anti-spike discrepants, particularly given that anti-N antibodies tend to appear before anti-spike antibodies (36, 37). All three of the individuals who were Abbott IgG positive prior to departure but lacked neutralizing and anti-spike antibodies and were RT-PCR positive upon return showed strong increases in index value. In addition, two of these three individuals had pre-departure Abbott index values that were close to the positivity cut-off. Unfortunately, we did not have sufficient residual pre-departure serum to run on a separate anti-N platform such as the Roche Elecsys anti-SARS-CoV-2 (50).

This study is limited by lack of information on clinical symptoms for the majority of crewmembers on the vessel and direct knowledge of contacts on the boat. We cannot also necessarily know that the three individuals with neutralizing antibodies prior to departure were exposed directly to SARS-CoV-2 on the vessel. The study is also limited by the low seroprevalence in the predeparture cohort---which is consistent with the approximate seroprevalence in May 2020 in the Seattle area, but means that there were only three individuals with pre-existing neutralizing antibodies. Nonetheless, with an overall attack rate of >85%, the lack of infection in the three individuals with neutralizing antibodies was statistically significant compared to the rest of the boat's crew. Overall, our results provide the first direct evidence anti-SARS-CoV-2 neutralizing antibodies are protective against SARS-CoV-2 infection in humans.

Acknowledgements

The authors thank Nicole Lieberman for helpful comments and Nathan Breit for data pulls. We also thank Brooke Fiala, Samuel Wrenn, Deleah Pettie, and Neil P. King at the Institute for Protein Design for sharing reagents for ELISA assays. Work performed in the clinical laboratory was supported by the Department of Laboratory Medicine and Pathology. This research was supported by the following grants from the NIAID of the NIH: R01AI141707 (to J.D.B.) and F30AI149928 (to K.H.D.C.). J.D.B. is an Investigator of the Howard Hughes Medical Institute.

References

388

389 Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, 1. 390 O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N, 391 Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin 392 BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd J-PM, Pessaint L, Van 393 Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell T-A, Cook A, 394 Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, 395 Zhou T, Teng I-T, Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-396 Jones G, Himansu S, Kong W-P, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, 397 Gaudinski MR, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore 398 IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. 2020. Evaluation of the mRNA-1273 399 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine 400 0:null. 401 2. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, 402 Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, 403 Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, 404 Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, 405 Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, 406 Munster VJ. 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus 407 macagues. Nature 1–8.

408 3. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, 409 Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, 410 Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. 2020. Development of an 411 inactivated vaccine candidate for SARS-CoV-2. Science 369:77-81. 412 Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, 4. 413 Haagmans BL, Grosveld F, Bosch B-J. 2020. A human monoclonal antibody blocking SARS-414 CoV-2 infection. Nat Commun 11:2251. 415 5. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, 416 Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, Zhang L. 417 2020. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 418 https://doi.org/10.1038/s41586-020-2380-z. 419 6. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, Muecksch F, Rutkowska 420 M, Hoffmann H-H, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, 421 Cipolla M. Luchsinger L. Hillver CD. Caskev M. Robbiani DF. Rice CM. Nussenzweig MC. 422 Hatziioannou T, Bieniasz PD. 2020. Escape from neutralizing antibodies by SARS-CoV-2 423 spike protein variants. bioRxiv 2020.07.21.214759. 424 7. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF-W, Sahi V, Figueroa A, Guo 425 XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen K-Y, Kwong PD, Sodroski JG, Yin 426 MT, Sheng Z, Huang Y, Shapiro L, Ho DD. 2020. Potent neutralizing antibodies directed to 427 multiple epitopes on SARS-CoV-2 spike. Nature 1–10.

428 8. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, Limbo O, Smith C, Song G, Woehl 429 J, Yang L, Abbott RK, Callaghan S, Garcia E, Hurtado J, Parren M, Peng L, Ramirez S, Ricketts 430 J, Ricciardi MJ, Rawlings SA, Wu NC, Yuan M, Smith DM, Nemazee D, Teijaro JR, Voss JE, 431 Wilson IA, Andrabi R, Briney B, Landais E, Sok D, Jardine JG, Burton DR. 2020. Isolation of 432 potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal 433 model. Science https://doi.org/10.1126/science.abc7520. 434 9. Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, McCune BT, Fox JM, 435 Chen RE, Alsoussi WB, Turner JS, Schmitz AJ, Lei T, Shrihari S, Keeler SP, Fremont DH, 436 Greco S, McCray PB, Perlman S, Holtzman MJ, Ellebedy AH, Diamond MS. 2020. A SARS-437 CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. Cell https://doi.org/10.1016/j.cell.2020.06.011. 438 439 10. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu 440 J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, 441 Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, 442 Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, 443 Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, 444 Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, 445 Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG, Barouch DH. 2020. SARS-CoV-2 446 infection protects against rechallenge in rhesus macaques. Science 447 https://doi.org/10.1126/science.abc4776.

448 11. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan 449 K, Tostanoski LH, He X, Martinez DR, Rutten L, Bos R, van Manen D, Vellinga J, Custers J, 450 Langedijk JP, Kwaks T, Bakkers MJG, Zuijdgeest D, Huber SKR, Atyeo C, Fischinger S, Burke 451 JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Hoffman E, 452 Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield LF, Nampanya F, 453 Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Ry AV, 454 Blade K, Strasbaugh A, Cabus M, Brown R, Cook A, Zouantchangadou S, Teow E, Andersen 455 H, Lewis MG, Cai Y, Chen B, Schmidt AG, Reeves RK, Baric RS, Lauffenburger DA, Alter G, 456 Stoffels P, Mammen M, Hoof JV, Schuitemaker H, Barouch DH. 2020. Single-shot Ad26 457 vaccine protects against SARS-CoV-2 in rhesus macagues. Nature https://doi.org/10.1038/s41586-020-2607-z. 458 459 12. Eyal N, Lipsitch M, Smith PG. 2020. Human Challenge Studies to Accelerate Coronavirus 460 Vaccine Licensure. J Infect Dis 221:1752–1756. 461 13. Nguyen LC, Bakerlee CW, McKelvey TG, Rose SM, Norman AJ, Joseph N, Manheim D, 462 McLaren MR, Jiang S, Barnes CF, Kinniment M, Foster D, Darton TC, Morrison J, 1Day 463 Sooner Research Team. 2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development. Clin Infect Dis 464 465 https://doi.org/10.1093/cid/ciaa935. 466 Dawson L, Earl J, Livezey J. 2020. Severe Acute Respiratory Syndrome Coronavirus 2 467 Human Challenge Trials: Too Risky, Too Soon. J Infect Dis 222:514–516.

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

15. Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Lynch HF, Jamrozik E, Jecker NS, Kamuya D, Kapulu M, Kimmelman J, MacKay D, Memoli MJ, Murphy SC, Palacios R, Richie TL, Roestenberg M, Saxena A, Saylor K, Selgelid MJ, Vaswani V, Rid A. 2020. Ethics of controlled human infection to address COVID-19. Science 368:832-834. Moriarty LF, Plucinski MM, Marston BJ, Kurbatova EV, Knust B, Murray EL, Pesik N, Rose D, Fitter D, Kobayashi M, Toda M, Cantey PT, Scheuer T, Halsey ES, Cohen NJ, Stockman L, Wadford DA, Medley AM, Green G, Regan JJ, Tardivel K, White S, Brown C, Morales C, Yen C, Wittry B, Freeland A, Naramore S, Novak RT, Daigle D, Weinberg M, Acosta A, Herzig C, Kapella BK, Jacobson KR, Lamba K, Ishizumi A, Sarisky J, Svendsen E, Blocher T, Wu C, Charles J, Wagner R, Stewart A, Mead PS, Kurylo E, Campbell S, Murray R, Weidle P, Cetron M, Friedman CR, CDC Cruise Ship Response Team, California Department of Public Health COVID-19 Team, Solano County COVID-19 Team, 2020, Public Health Responses to COVID-19 Outbreaks on Cruise Ships - Worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep 69:347-352. 17. Kakimoto K, Kamiya H, Yamagishi T, Matsui T, Suzuki M, Wakita T. 2020. Initial Investigation of Transmission of COVID-19 Among Crew Members During Quarantine of a Cruise Ship - Yokohama, Japan, February 2020. MMWR Morb Mortal Wkly Rep 69:312-313. Payne DC, Smith-Jeffcoat SE, Nowak G, Chukwuma U, Geibe JR, Hawkins RJ, Johnson JA, Thornburg NJ, Schiffer J, Weiner Z, Bankamp B, Bowen MD, MacNeil A, Patel MR, Deussing E, CDC COVID-19 Surge Laboratory Group, Gillingham BL. 2020. SARS-CoV-2 Infections and

489		Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore
490		Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep 69:714–721.
491	19.	Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
492		Comparison of Commercially Available and Laboratory Developed Assays for in vitro
493		Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol
494		https://doi.org/10.1128/JCM.00821-20.
495	20.	Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias
496		PC, Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2
497		IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol
498		https://doi.org/10.1128/JCM.00941-20.
499	21.	Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H,
500		Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection
501		Assays using Seven Different Primer/Probe Sets and One Assay Kit. J Clin Microbiol
502		https://doi.org/10.1128/JCM.00557-20.
503	22.	Addetia A, Xie H, Roychoudhury P, Shrestha L, Loprieno M, Huang M-L, Jerome KR,
504		Greninger AL. 2020. Identification of multiple large deletions in ORF7a resulting in in-
505		frame gene fusions in clinical SARS-CoV-2 isolates. J Clin Virol 129:104523.
506	23.	Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods
507		9:357–359.

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

24. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. 25. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol https://doi.org/10.1038/s41564-020-0770-5. 26. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. 27. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS ONE 5:e9490. 28. Yu G. 2020. Using ggtree to Visualize Data on Tree-Like Structures. Curr Protoc Bioinformatics 69:e96. 29. Crawford KH, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, Pettie D, King NP, Chu HY, Bloom JD. 2020. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv 2020.08.06.20169367. 30. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K, Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM,

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

Simon V, Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 26:1033-1036. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F. 2020. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 57:e100. 32. Dingens AS, Crawford KH, Adler A, Steele SL, Lacombe K, Eguia R, Amanat F, Walls AC, Wolf CR, Murphy M, Pettie D, Carter L, Qin X, King NP, Veesler D, Krammer F, Dickerson JA, Chu HY, Englund JA, Bloom JD. 2020. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. medRxiv 2020.05.26.20114124. 33. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 12. 34. Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, O'Bryne A, Kouphou N, Pickering S, Galao R, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C, Temperton N, Snell L, Bisnauthsing K, Moore A, Green A, Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, OConnell L, Hara GO, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Edgeworth JD, Neil SJD, Malim MH, Doores K. 2020.

548 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. 549 medRxiv 2020.07.09.20148429. 550 35. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, 551 Gazumyan A, Finkin S, Hägglöf T, Oliveira TY, Viant C, Hurley A, Hoffmann H-H, Millard KG, 552 Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich 553 I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, 554 Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, 555 West AP, Rice CM, Hatziioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC. 556 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 557 https://doi.org/10.1038/s41586-020-2456-9. 558 36. Hachim A, Kavian N, Cohen CA, Chin AW, Chu DK, Mok CKP, Tsang OT, Yeung YC, Perera 559 RA, Poon LL, Peiris MJ, Valkenburg SA. 2020. Beyond the Spike: identification of viral 560 targets of the antibody response to SARS-CoV-2 in COVID-19 patients. medRxiv 561 2020.04.30.20085670. 562 37. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR, Chertow DS, 563 Davey RT, Cohen JI. 2020. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike 564 Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis 222:206-213. 565

566	38.	Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal
567		patterns of nucleic acid and serology testing results based on disease severity of COVID-19
568		patients. Emerging Microbes & Infections 9:833–836.
569	39.	Lee Y-L, Liao C-H, Liu P-Y, Cheng C-Y, Chung M-Y, Liu C-E, Chang S-Y, Hsueh P-R. 2020.
570		Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect
571		81:e55–e58.
572	40.	Li N, Wang X, Lv T. 2020. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. J
573		Med Virol https://doi.org/10.1002/jmv.25952.
574	41.	Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu
575		H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin
576		C. 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
577		Science https://doi.org/10.1126/science.abc5343.
578	42.	Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E,
579		Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S,
580		Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna
581		TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS,
582		Alter G, Ryan ET, Harris JB, Charles RC. 2020. Dynamics and significance of the antibody
583		response to SARS-CoV-2 infection. medRxiv
584		https://doi.org/10.1101/2020.07.18.20155374.

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

43. Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J, Castillo B, Leveque C, Towers DM, Lavinder J, Gollihar JD, Cardona J, Ippolito GC, Nissly RH, Bird IM, Greenawalt D, Rossi RM, Gontu A, Srinivasan S, Poojary IB, Cattadori IM, Hudson PJ, Joselyn N, Prugar L, Huie K, Herbert A, Bernard DW, Dye J, Kapur V, Musser JM. 2020. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv https://doi.org/10.1101/2020.06.08.138990. 44. Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, Loudermilk R, Chiu CY, Wilson MR, Leung KK, Wells JA. 2020. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding. medRxiv https://doi.org/10.1101/2020.05.27.20114652. 45. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395:1054-1062. 46. Fang FC, Naccache SN, Greninger AL. 2020. The Laboratory Diagnosis of COVID-19--Frequently-Asked Questions. Clin Infect Dis https://doi.org/10.1093/cid/ciaa742. 47. Bryan A, Fink SL, Gattuso MA, Pepper G, Chaudhary A, Wener M, Morishima C, Jerome K, Mathias PC, Greninger AL. 2020. Anti-SARS-CoV-2 IgG antibodies are associated with reduced viral load. medRxiv 2020.05.22.20110551.

Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. 2020. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clin Chem 66:1055–1062.
 Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst M, Lagrou K, Vermeersch P. 2020. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs. Clinical Microbiology and Infection https://doi.org/10.1016/j.cmi.2020.07.038.
 Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. 2020. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem 66:1107–1109.

Supplemental Table 1 – SARS-CoV-2 isolates and accessions sequenced in this study.

617

618

Isolate	GISAID Accession Number
USA/WA-UW-10027/2020	EPI_ISL_461450
USA/WA-UW-10028/2020	EPI_ISL_461451
USA/WA-UW-10029/2020	EPI_ISL_461452
USA/WA-UW-10030/2020	EPI_ISL_511852
USA/WA-UW-10031/2020	EPI_ISL_461453
USA/WA-UW-10034/2020	EPI_ISL_511853
USA/WA-UW-10036/2020	EPI_ISL_461454
USA/WA-UW-10038/2020	EPI_ISL_511854
USA/WA-UW-10039/2020	EPI_ISL_461455
USA/WA-UW-10040/2020	EPI_ISL_461456
USA/WA-UW-10042/2020	EPI_ISL_461457
USA/WA-UW-10088/2020	EPI_ISL_461458
USA/WA-UW-10089/2020	EPI_ISL_461459
USA/WA-UW-10090/2020	EPI_ISL_461460
USA/WA-UW-10091/2020	EPI_ISL_461461
USA/WA-UW-10093/2020	EPI_ISL_461462
USA/WA-UW-10094/2020	EPI_ISL_461463
USA/WA-UW-10101/2020	EPI_ISL_511855
USA/WA-UW-10102/2020	EPI_ISL_461464
USA/WA-UW-10105/2020	EPI_ISL_511856
USA/WA-UW-10106/2020	EPI_ISL_461465
USA/WA-UW-10107/2020	EPI_ISL_461466
USA/WA-UW-10108/2020	EPI_ISL_461467
USA/WA-UW-10113/2020	EPI_ISL_511857
USA/WA-UW-10114/2020	EPI_ISL_461468
USA/WA-UW-10115/2020	EPI_ISL_511858
USA/WA-UW-10116/2020	EPI_ISL_512086
USA/WA-UW-10117/2020	EPI_ISL_461469
USA/WA-UW-10118/2020	EPI_ISL_461470
USA/WA-UW-10124/2020	EPI_ISL_511859
USA/WA-UW-10126/2020	EPI_ISL_511860
USA/WA-UW-10127/2020	EPI_ISL_461471
USA/WA-UW-10128/2020	EPI_ISL_461472
USA/WA-UW-10129/2020	EPI_ISL_461473
USA/WA-UW-10130/2020	EPI_ISL_461474
USA/WA-UW-10131/2020	EPI_ISL_461475
USA/WA-UW-10133/2020	EPI_ISL_511861
USA/WA-UW-10136/2020	EPI_ISL_461476
USA/WA-UW-10138/2020	EPI_ISL_461477

32